Form 4 for AVLN Avalyn Pharma Inc.
Accepted 2026-05-01 18:26:58 ET · period of report 2026-05-01 · accession 0001193125-26-201863 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-01 18:26 | 2026-05-01 | AVLN | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% | C - Cnv Deriv | — | +1.28M | 1.28M | New | — |
| DM | 2026-05-01 18:26 | 2026-05-01 | AVLN | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% | C - Cnv Deriv | $0.00 | -24.54M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | C | A | 1,275,486 | — | 1,275,486 | D | — | — | (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |
| 2 | Derivative | Series C-1 Convertible Preferred Stock | 2026-05-01 | C | D | 20,482,289 | $0.00 | 0 | D | — · — to — | 1,064,473 Common Stock | (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |
| 3 | Derivative | Series D Convertible Preferred Stock | 2026-05-01 | C | D | 4,060,259 | $0.00 | 0 | D | — · — to — | 211,013 Common Stock | (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date. |